In this follow-up to my keynote presentation at the meeting of the North Carolina Regulatory Affairs Forum (NCRAF) in conjunction with the Triangle Chapter of the ACRP, I’m reflecting— full-chested and unfiltered— on what it means to be voice-activated in an ecosystem that still hasn’t gotten the memo. Among other themes, I’m talking about the fallacy of “coercion” when it comes to compensating participants. I’m calling out the lazy copy/paste of outdated inclusion/exclusion criteria that keep too many out—and keep our data from ever being truly equitable or personalized. I’m challenging regulatory professionals to take action with something as simple and impactful as a “find and replace” to retire the word subject once and for all.

This isn’t just critique. It’s a call to courage. A love letter to those of us who’ve been in the research chair— and a charge to those in power to shift how we show up.

This was only the tip of the iceberg… and now it’s time to melt what’s been frozen far too long. Get the 'voice-activated' t-shirt to demonstrate your intentions. Read my 'Equity 'N Action' newsletter article on LinkedIn on the same topic. Still more at www.allisonkalloo.me.

#VoiceActivated #ClinicalResearchReckoning #NCRAF #ACRP #NCRAF2025 #ACRPVoices #ParticipantPerspective #RegulatoryReformNow #CompensateFairly #InclusionNotIllusion #FindAndReplace #DataWithDignity #EthicsInAction #TechForTrust #TrialParticipantsMatter #Partners #ICF #Coercion #Compensation #IECriteria #ProtocolDesign #Bias #BakedInBias #PersonalizedMedicine #Iceberg

Send us a text

#ClinicalTrials #HealthEquity #DiversityInResearch #UnderrepresentedCommunities #ClinicalResearch #Biopharma #RegulatoryAgencies #CROs #PatientAdvocacy #HealthInnovation #NoOrdinarySubjects #Podcast #HealthPodcast #MedicalResearch #ClinicalResearch #InclusionInResearch #HealthDisparities #PrecisionMedicine #PersonalizedMedicine #PatientCentricity #ResearchEthics #FDA #NIH #EquityInHealth #ChangeTheStatusQuo #MeaningfulSolutions #DEIinHealthcare #HealthDisparities #InclusionInResearch #PatientAdvocacy #PatientStories #HealthPolicy #HealthInnovation #Biotech #Pharmaceuticals #MedicalPodcast #EquityInHealth #RepresentationMatters #UnconsciousBias #CulturalCompetency #HealthJustice #ResearchEthics #UnderrepresentedCommunities #HealthOutcomes #ClinicalCare #HealthResearch

#MedicalResearch #Healthcare #TransparencyInResearch #TruthInTrials  #ResearchEthics #CommunityEngagement #RadicalTransparency #NoOrdinarySubjects #AllisonKalloo #ResearchTransparency #BeyondTrust #MarginalizedCommunities  #SystemicInequality #HistoricalTraumaInResearch #DEIinResearch #DataTransparency #AskTheQuestions #DemandTransparency #InformedChoice #PowerToThePeople #April2025

Send us a text

#ClinicalTrials #HealthEquity #DiversityInResearch #UnderrepresentedCommunities #ClinicalResearch #Biopharma #RegulatoryAgencies #CROs #PatientAdvocacy #HealthInnovation #NoOrdinarySubjects #Podcast #HealthPodcast #MedicalResearch #ClinicalResearch #InclusionInResearch #HealthDisparities #PrecisionMedicine #PersonalizedMedicine #PatientCentricity #ResearchEthics #FDA #NIH #EquityInHealth #ChangeTheStatusQuo #MeaningfulSolutions #DEIinHealthcare #HealthDisparities #InclusionInResearch #PatientAdvocacy #PatientStories #HealthPolicy #HealthInnovation #Biotech #Pharmaceuticals #MedicalPodcast #EquityInHealth #RepresentationMatters #UnconsciousBias #CulturalCompetency #HealthJustice #ResearchEthics #UnderrepresentedCommunities #HealthOutcomes #ClinicalCare #HealthResearch

This episode of No Ordinary Subjects confronts the return of measles in the United States— a disease we once eliminated. We explore how rising vaccine hesitancy, fueled by years of politicized misinformation and erosion of public trust, has weakened our collective defenses and put us back at risk. Drawing connections between the sidelining of science during the COVID pandemic and today’s outbreaks, we dig into what herd immunity means, who gets left behind and at risk when it's compromised, and why protecting public health demands reconciliation with science-based expertise and the facts.

#NoOrdinarySubjects #Measles #Vaccination #Immunity #Outbreak  
#PublicHealth #PublicHealthCrisis #HerdImmunity #VaccineHesitancy  
#TrustScience #ScienceNotSilence #StopTheSpread #MisinformationKills  
#ProtectOurKids #HealthEquity #HealthJustice #CommunityImmunity  
#FactsMatter #ThisIsPreventable #WakeUpCall #ReclaimPublicHealth  

Send us a text

#ClinicalTrials #HealthEquity #DiversityInResearch #UnderrepresentedCommunities #ClinicalResearch #Biopharma #RegulatoryAgencies #CROs #PatientAdvocacy #HealthInnovation #NoOrdinarySubjects #Podcast #HealthPodcast #MedicalResearch #ClinicalResearch #InclusionInResearch #HealthDisparities #PrecisionMedicine #PersonalizedMedicine #PatientCentricity #ResearchEthics #FDA #NIH #EquityInHealth #ChangeTheStatusQuo #MeaningfulSolutions #DEIinHealthcare #HealthDisparities #InclusionInResearch #PatientAdvocacy #PatientStories #HealthPolicy #HealthInnovation #Biotech #Pharmaceuticals #MedicalPodcast #EquityInHealth #RepresentationMatters #UnconsciousBias #CulturalCompetency #HealthJustice #ResearchEthics #UnderrepresentedCommunities #HealthOutcomes #ClinicalCare #HealthResearch

In this episode of No Ordinary Subjects, host Allison Kalloo unpacks the dangerous implications of the Trump administration’s latest executive order, Restoring Truth and Sanity to American History, which takes direct aim at the Smithsonian Institution—specifically, the National Museum of African American History and Culture. This isn’t just about rewriting history; it’s about erasing it.

We explore how this calculated attack on historical integrity threatens not only cultural institutions but also industries that rely on truth—healthcare, technology, and business. What happens when systemic erasure extends to medical research, clinical trials, and AI development? What’s at stake when Black contributions are deliberately excluded from the national consciousness?

This episode is a call to action. Beyond passive allyship, we discuss what it means to be an accomplice in the fight for truth. Because neutrality is not an option when history itself is under siege.

Join the conversation.

Send us a text

#ClinicalTrials #HealthEquity #DiversityInResearch #UnderrepresentedCommunities #ClinicalResearch #Biopharma #RegulatoryAgencies #CROs #PatientAdvocacy #HealthInnovation #NoOrdinarySubjects #Podcast #HealthPodcast #MedicalResearch #ClinicalResearch #InclusionInResearch #HealthDisparities #PrecisionMedicine #PersonalizedMedicine #PatientCentricity #ResearchEthics #FDA #NIH #EquityInHealth #ChangeTheStatusQuo #MeaningfulSolutions #DEIinHealthcare #HealthDisparities #InclusionInResearch #PatientAdvocacy #PatientStories #HealthPolicy #HealthInnovation #Biotech #Pharmaceuticals #MedicalPodcast #EquityInHealth #RepresentationMatters #UnconsciousBias #CulturalCompetency #HealthJustice #ResearchEthics #UnderrepresentedCommunities #HealthOutcomes #ClinicalCare #HealthResearch

In this episode of No Ordinary Subjects, host Allison Kalloo exposes a critical flaw in how clinical trials are regulated in the U.S. The FDA can issue guidance, make recommendations, and encourage diversity— but it lacks the power to enforce meaningful change. Without Congressional action, clinical trial sponsors can continue treating inclusion as optional. It’s time to demand more than suggestions. Tune in for a frank discussion on why the FDA needs real authority and what’s at stake if we keep accepting business as usual. Read the companion article on LinkedIn.

#NoOrdinarySubjects #RegulatoryPower #PatientAdvocacy #PublicHealth #HealthcarePolicy #DrugApproval

Send us a text

#ClinicalTrials #HealthEquity #DiversityInResearch #UnderrepresentedCommunities #ClinicalResearch #Biopharma #RegulatoryAgencies #CROs #PatientAdvocacy #HealthInnovation #NoOrdinarySubjects #Podcast #HealthPodcast #MedicalResearch #ClinicalResearch #InclusionInResearch #HealthDisparities #PrecisionMedicine #PersonalizedMedicine #PatientCentricity #ResearchEthics #FDA #NIH #EquityInHealth #ChangeTheStatusQuo #MeaningfulSolutions #DEIinHealthcare #HealthDisparities #InclusionInResearch #PatientAdvocacy #PatientStories #HealthPolicy #HealthInnovation #Biotech #Pharmaceuticals #MedicalPodcast #EquityInHealth #RepresentationMatters #UnconsciousBias #CulturalCompetency #HealthJustice #ResearchEthics #UnderrepresentedCommunities #HealthOutcomes #ClinicalCare #HealthResearch

This episode of No Ordinary Subjects gets into the ethical complexities of the $24 billion plasma donation industry and the "Plasma Paradox": the vast financial gap between donor compensation and the multi-thousand dollar value of plasma-derived pharmaceuticals that come from each liter extracted. Examining the fairness of corporate profits versus donor payouts, also consider the long-term health effects of frequent plasma extraction. The episode covers the history of plasma use and life-saving therapies, financial disparities, and ethical concerns, and calls for more regulation, transparency, community investment, informed consent, and equitable compensation. There is credence in challenging the idea that altruism negates fair pay. This is a rallying cry for a system that truly values donors and the vital role they play in access to better health outcomes.

#PlasmaDonation #EthicalDilemmas #HealthcareEquity #MedicalEthics #PharmaceuticalIndustry #DonorCompensation #BloodPlasma #HumanRights #MedicalResearch #IndustryProfits #VulnerablePopulations #InformedConsent #MedicalJustice #HealthDisparities #EconomicVulnerability #HenriettaLacks #AltruismVsProfit #PatientRights #MedicalRegulation #NoOrdinarySubjects #BloodDonation #Healthcare #DonorRights #PatientRights #HealthEquity #Pharmaceuticals #CommunityHealth #FairCompensation #EconomicJustice #HealthAccess #MedicalIndustry #HealthAwareness #DonatePlasma #DonateBlood #MedicalDebate #HealthPolicy #PublicHealth #PlasmaIndustry #BloodIndustry #MedicalProfits #DonorExploitation #MedicalTransparency #HealthcareReform #Bioethics #MedicalInnovation #DrugPricing #HealthEconomics #ClinicalTrials #MedicalAdvocacy #HealthcareForAll #HealthJustice #health #blood #plasma #donation #savealife #hemoglobin #protein #iron #sicklecell #plasmaexchange #deficiencydisease #hemophilia #PID #immunodeficiencydisease #IGtherapy #pharma #medicine #justice #equity #medicalethics #donateplasma #poverty #SDOH #socialdeterminantsofhealth

Send us a text

#ClinicalTrials #HealthEquity #DiversityInResearch #UnderrepresentedCommunities #ClinicalResearch #Biopharma #RegulatoryAgencies #CROs #PatientAdvocacy #HealthInnovation #NoOrdinarySubjects #Podcast #HealthPodcast #MedicalResearch #ClinicalResearch #InclusionInResearch #HealthDisparities #PrecisionMedicine #PersonalizedMedicine #PatientCentricity #ResearchEthics #FDA #NIH #EquityInHealth #ChangeTheStatusQuo #MeaningfulSolutions #DEIinHealthcare #HealthDisparities #InclusionInResearch #PatientAdvocacy #PatientStories #HealthPolicy #HealthInnovation #Biotech #Pharmaceuticals #MedicalPodcast #EquityInHealth #RepresentationMatters #UnconsciousBias #CulturalCompetency #HealthJustice #ResearchEthics #UnderrepresentedCommunities #HealthOutcomes #ClinicalCare #HealthResearch

Tune in to this episode to get guidance on cutting through DEI noise to deliver actionable guidelines for clinical trial equity. Learn how to move beyond buzzwords, meet FDA expectations, and create real change. We cover lived experience, recruitment, community partnerships, data strategies, and more. We're speaking directly to Clinical Trial Operations Leaders, Regulatory Affairs professionals, Medical Affairs experts, Heads of DEI, Biotech Founders, CRO Executives, and Patient Advocates. If you're grappling with recruitment challenges, navigating evolving FDA diversity guidance, or striving for meaningful change beyond corporate statements, this episode is for you. After all, DEI in clinical trials is ultimately centered on producing better science, better business, and better patient outcomes.

#DEI #DiversityInclusion #HealthcareEquity #PatientAdvocacy #Pharma #Biotech #RegulatoryAffairs #MedicalAffairs #FDA #ClinicalResearch #HealthDisparities #CommunityHealth #DataDriven #PatientExperience #ResearchEthics #HealthInnovation #PublicHealth #ScientificResearch #HealthTech #Equity

Send us a text

#ClinicalTrials #HealthEquity #DiversityInResearch #UnderrepresentedCommunities #ClinicalResearch #Biopharma #RegulatoryAgencies #CROs #PatientAdvocacy #HealthInnovation #NoOrdinarySubjects #Podcast #HealthPodcast #MedicalResearch #ClinicalResearch #InclusionInResearch #HealthDisparities #PrecisionMedicine #PersonalizedMedicine #PatientCentricity #ResearchEthics #FDA #NIH #EquityInHealth #ChangeTheStatusQuo #MeaningfulSolutions #DEIinHealthcare #HealthDisparities #InclusionInResearch #PatientAdvocacy #PatientStories #HealthPolicy #HealthInnovation #Biotech #Pharmaceuticals #MedicalPodcast #EquityInHealth #RepresentationMatters #UnconsciousBias #CulturalCompetency #HealthJustice #ResearchEthics #UnderrepresentedCommunities #HealthOutcomes #ClinicalCare #HealthResearch

Our perspectives and opportunities are shaped by culture, history, and the experiences we carry. On this International Women’s Day episode of No Ordinary Subjects, we’re celebrating how these forces influence the way we move through the world— and how we can push beyond the limits they impose. It’s also about not allowing competition with one another impede our progress or diminish our community. Women are stepping fully into our power. From resilience to reinvention, women continue to transform obstacles into opportunities. 

Send us a text

#ClinicalTrials #HealthEquity #DiversityInResearch #UnderrepresentedCommunities #ClinicalResearch #Biopharma #RegulatoryAgencies #CROs #PatientAdvocacy #HealthInnovation #NoOrdinarySubjects #Podcast #HealthPodcast #MedicalResearch #ClinicalResearch #InclusionInResearch #HealthDisparities #PrecisionMedicine #PersonalizedMedicine #PatientCentricity #ResearchEthics #FDA #NIH #EquityInHealth #ChangeTheStatusQuo #MeaningfulSolutions #DEIinHealthcare #HealthDisparities #InclusionInResearch #PatientAdvocacy #PatientStories #HealthPolicy #HealthInnovation #Biotech #Pharmaceuticals #MedicalPodcast #EquityInHealth #RepresentationMatters #UnconsciousBias #CulturalCompetency #HealthJustice #ResearchEthics #UnderrepresentedCommunities #HealthOutcomes #ClinicalCare #HealthResearch

Lately, there’s been a shift: Companies and institutions that were always genuine about cultural change are finding themselves needing to “rebrand” diversity, equity, and inclusion (DEI) in light of the toxic political climate. But let’s be real: Is this adaptive evolution or erosion of standards? In this episode of No Ordinary Subjects, I break down the difference between meaningful transformation and the kind of corporate posturing that prioritizes optics over impact. For those genuinely deeply invested in inclusive strategies—especially in healthcare and clinical trials— you earn respect for refusing to acquiesce to the political toxicity that’s made DEI a dirty word in some circles. And for not cosigning on professional peer pressure that waters down what true equity requires. Instead, we’ll talk about what authenticity in DEI looks like, why community engagement and transparency are non-negotiable, and how we keep our eyes on the prize and move forward without losing the plot. If you’re tired of lip service and looking for real talk on DEI, this episode is for you.

Send us a text

#ClinicalTrials #HealthEquity #DiversityInResearch #UnderrepresentedCommunities #ClinicalResearch #Biopharma #RegulatoryAgencies #CROs #PatientAdvocacy #HealthInnovation #NoOrdinarySubjects #Podcast #HealthPodcast #MedicalResearch #ClinicalResearch #InclusionInResearch #HealthDisparities #PrecisionMedicine #PersonalizedMedicine #PatientCentricity #ResearchEthics #FDA #NIH #EquityInHealth #ChangeTheStatusQuo #MeaningfulSolutions #DEIinHealthcare #HealthDisparities #InclusionInResearch #PatientAdvocacy #PatientStories #HealthPolicy #HealthInnovation #Biotech #Pharmaceuticals #MedicalPodcast #EquityInHealth #RepresentationMatters #UnconsciousBias #CulturalCompetency #HealthJustice #ResearchEthics #UnderrepresentedCommunities #HealthOutcomes #ClinicalCare #HealthResearch

DEI is under attack—watered down, defunded, and dismissed. But let’s be clear: its death is neither inevitable nor acceptable. In this episode of No Ordinary Subjects, I confront the backlash against diversity, equity, and inclusion head-on, exposing the paranoid hypocrisy of those who claim DEI has "gone too far" while systemic inequities remain as stark as ever. I call out the performative gestures and demand accountability. From empty corporate pledges to outright rollbacks, I call out the administration for fueling this backlash with their paranoid, regressive narrative. DEI isn’t a trend—it’s a fixture, no matter what you want to call it. Because on my watch, silence is not an option. 

Send us a text

#ClinicalTrials #HealthEquity #DiversityInResearch #UnderrepresentedCommunities #ClinicalResearch #Biopharma #RegulatoryAgencies #CROs #PatientAdvocacy #HealthInnovation #NoOrdinarySubjects #Podcast #HealthPodcast #MedicalResearch #ClinicalResearch #InclusionInResearch #HealthDisparities #PrecisionMedicine #PersonalizedMedicine #PatientCentricity #ResearchEthics #FDA #NIH #EquityInHealth #ChangeTheStatusQuo #MeaningfulSolutions #DEIinHealthcare #HealthDisparities #InclusionInResearch #PatientAdvocacy #PatientStories #HealthPolicy #HealthInnovation #Biotech #Pharmaceuticals #MedicalPodcast #EquityInHealth #RepresentationMatters #UnconsciousBias #CulturalCompetency #HealthJustice #ResearchEthics #UnderrepresentedCommunities #HealthOutcomes #ClinicalCare #HealthResearch